Adamantane Derivatives Inhibiting Filovirus Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies lack effective solutions for inhibiting the infection of filoviruses, such as Ebola and Marburg, which cause severe hemorrhagic fevers with high mortality rates.
Innovation Solution
The use of compounds represented by Structural Formula I, or their pharmaceutically acceptable salts, which are administered to inhibit filovirus infection by targeting the cell entry process mediated by filovirus glycoproteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral therapies are used, then treatment of other enveloped viruses is possible, but effective inhibition of filovirus infection is lacking
Solution Approach 1:
The patent develops adamantane derivative compounds that function as broad-spectrum antivirals effective against multiple enveloped virus families including Filoviridae, Coronaviridae, Flaviviridae, and others. These compounds target conserved viral entry mechanisms shared across different enveloped viruses, enabling a single therapeutic agent to address multiple viral threats simultaneously.
Solution Approach 2:
The invention modifies the chemical structure of adamantane derivatives by varying substituents at different positions (R1-R10 groups) to optimize antiviral activity. By changing molecular parameters such as hydrophobicity, steric bulk, and electronic properties, the compounds achieve enhanced potency and selectivity against filoviruses while maintaining broad-spectrum activity.
2Object-affected harmful factors
If compounds targeting filovirus glycoproteins are developed, then filovirus infection is inhibited, but lack of effective antiviral solutions for high mortality rates persists
Solution Approach 1:
The adamantane derivative compounds intervene at the very initial stage of viral infection by blocking glycoprotein-mediated cell entry. By preventing virus attachment and fusion with host cells before replication begins, these compounds stop the infection cascade early, reducing viral load and preventing the progression to severe disease and high mortality.
Solution Approach 2:
The compounds act as molecular intermediaries that interfere with the interaction between filovirus glycoproteins and host cell receptors. The adamantane core structure with specific substituents serves as a steric and chemical barrier, blocking the glycoprotein's ability to mediate membrane fusion without requiring direct contact with vulnerable viral components.
Data Source
AI summary
Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R1, R2, R3, X and Y are defined in the specification.